FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:1821-1822 December 9, 1993 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

To the Editor: As we previously reported (November 5, 1992, issue),¹ interferon alfa, when added to a four-drug, doxorubicin-based chemotherapy regimen, is an effective antitumor agent in patients with clinically aggressive low-grade or intermediate-grade non-Hodgkin's lymphoma. This study has now reached a median follow-up period for survival of 5.25 years. At five years, 81 percent of the patients assigned to a regimen of cyclophosphamide, vincristine, prednisone, and doxorubicin (COPA) and 66 percent of those assigned to this regimen plus interferon alfa (I-COPA) had disease progression. The time to treatment failure continues to be significantly prolonged (P = 0.0013) by the . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Rohatiner, A.Z.S., Gregory, W.M., Peterson, B., Borden, E., Solal-Celigny, P., Hagenbeek, A., Fisher, R.I., Unterhalt, M., Arranz, R., Chisesi, T., Aviles, A., Lister, T.A. (2005). Meta-Analysis to Evaluate the Role of Interferon in Follicular Lymphoma. JCO 23: 2215-2223 [Abstract] [Full Text]